Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies
- PMID: 33620732
- PMCID: PMC8555868
- DOI: 10.1002/cncr.33433
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies
Abstract
Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.
Keywords: chimeric antigen receptor T cells (CAR T cells); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor; immunotherapy; mesothelin; mesothelioma; programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor.
© 2021 American Cancer Society.
Conflict of interest statement
Conflict of interest:
RH has funding for conduct of clinical trials via a cooperative research and development agreement between NCI and Bayer AG and TCR2 Therapeutics. Other authors do not have any conflict of interests.
Similar articles
-
Nivolumab plus ipilimumab in malignant pleural mesothelioma.Expert Rev Anticancer Ther. 2022 Aug;22(8):815-822. doi: 10.1080/14737140.2022.2102482. Epub 2022 Jul 25. Expert Rev Anticancer Ther. 2022. PMID: 35835722
-
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.Drugs. 2021 Jun;81(9):971-984. doi: 10.1007/s40265-021-01506-0. Epub 2021 Jun 9. Drugs. 2021. PMID: 34106454 Review.
-
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2. Clin Lung Cancer. 2021. PMID: 33358660 No abstract available.
-
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.EBioMedicine. 2020 Dec;62:103040. doi: 10.1016/j.ebiom.2020.103040. Epub 2020 Nov 7. EBioMedicine. 2020. PMID: 33166791 Free PMC article.
-
Nivolumab for the treatment of unresectable pleural mesothelioma.Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16. Expert Opin Biol Ther. 2020. PMID: 31825692 Review.
Cited by
-
Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.J Cancer Res Clin Oncol. 2024 May 28;150(5):282. doi: 10.1007/s00432-024-05802-6. J Cancer Res Clin Oncol. 2024. PMID: 38806867 Free PMC article.
-
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.Mol Cancer. 2024 Apr 16;23(1):77. doi: 10.1186/s12943-024-01956-6. Mol Cancer. 2024. PMID: 38627681 Free PMC article. Review.
-
Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies.Int J Nanomedicine. 2024 Jan 20;19:633-650. doi: 10.2147/IJN.S435787. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38269255 Free PMC article.
-
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.Radiother Oncol. 2024 Feb;191:110057. doi: 10.1016/j.radonc.2023.110057. Epub 2023 Dec 15. Radiother Oncol. 2024. PMID: 38104783
-
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.Front Oncol. 2023 Apr 21;13:1156329. doi: 10.3389/fonc.2023.1156329. eCollection 2023. Front Oncol. 2023. PMID: 37152028 Free PMC article.
References
-
- Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17: 525–534. - PubMed
-
- Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available from URL: https://seer.cancer.gov/csr/1975_2016/.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials